Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Abecma
Pharma
FDA probes CAR-T therapies' 'serious risk' of secondary cancer
The FDA is investigating a “serious risk” of patients developing new cancers after treatment with these highly efficacious oncology drugs.
Angus Liu
Nov 28, 2023 1:16pm
FDA calls for adcomm on BMS's Abecma in earlier treatment line
Nov 20, 2023 11:30am
2seventy suffers CAR-T commercialization pitfalls with Abecma
Nov 15, 2023 11:10am
BMS has a plan to reinvigorate recent drug launches
Oct 26, 2023 11:45am
BMS taps Cellares for robotic production of pipeline CAR-T drug
Aug 29, 2023 8:35am
With Revlimid sales down, BMS slashes 2023 revenue projection
Jul 27, 2023 11:43am
